| |
Sequence AB
n = 12
|
Sequence BA
n = 13
|
All subjects treated
N = 25
|
All subjects completed
n = 22a
|
|---|
|
Baseline characteristics
| | | | |
|
Age (years)
| | | | |
|
Mean
|
38.0
|
35.2
|
36.5
|
36.3
|
|
SD
|
8.7
|
9.4
|
9.0
|
9.1
|
|
Height (cm)
| | | | |
|
Mean
|
183.2
|
176.0
|
179.4
|
178.6
|
|
SD
|
4.5
|
4.6
|
5.8
|
5.0
|
|
Weight (kg)
| | | | |
|
Mean
|
89.4
|
78.9
|
83.9
|
82.2
|
|
SD
|
12.5
|
8.4
|
11.7
|
10.6
|
|
BMI (kg/m2)
|
|
Mean
|
26.6
|
25.5
|
26.0
|
25.8
|
|
SD
|
3.3
|
2.6
|
2.9
|
3.0
|
|
Demographics
|
|
Ethnicity
|
|
Hispanic/Latino
|
1 (8.3%)
|
3 (23.1%)
|
4 (16.0%)
|
4 (18.2%)
|
|
Not Hispanic or Latino
|
11 (91.7%)
|
10 (76.9%)
|
21 (84.0%)
|
18 (81.8%)
|
|
Race
|
|
White
|
3 (25.0%)
|
7 (53.8%)
|
10 (40.0%)
|
8 (36.4%)
|
|
Black/African American
|
9 (75.0%)
|
5 (38.5%)
|
14 (56.0%)
|
13 (59.1%)
|
|
Asian
|
0 (0.0%)
|
1 (7.7%)
|
1 (4.0%)
|
1 (4.5%)
|
- Treatment A: AAFP 500 mg under fed conditions
- Treatment B: AAFP 500 mg under fasted conditions
-
AAFP abiraterone acetate fine particle, BMI body mass index, SD standard deviation
-
aTwo subjects were discontinued; one for violation of house rules and one for pre-existing increased blood pressure. One subject was lost to follow-up